Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function

Cancer Research

Volumn 57, Issue 18, 1997, Pages 4029-4035

  Shao, Rong Guang ^a   Cao, Chun Xia ^a   Shimizu, Tsunehiro ^a   O'Connor, Patrick M ^a   Kohn, Kurt W ^a   Pommier, Yves ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CAMPTOTHECIN; PROTEIN KINASE C INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE S PHASE; COLON CARCINOMA; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ALKALOIDS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE PROTEINS; DNA, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; GENES, P53; HUMANS; PROTEIN KINASE C; S PHASE; STAUROSPORINE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030870632     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51: 4888-4892, 1991.
2. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
3. Seynaeve, C. M., Kazanietz, M. G., Blumberg, P. M., Sausville, E. A., and Worland, P. J. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol. Pharmacol., 45: 1207-1214, 1994.
4. Mizuno, K., Noda, K., Ueda, Y., Hanaki, H., Saido, T. C., Ikuta, T., Kuroki, T., Tamaoki, T., Hirai, S., Osada, S., and Ohno, S. UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Lett., 359: 259-261, 1995.
5. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mulated human epidermoid carcinoma A431 cells. Cancer Res., 57: 1495-1501, 1997.
6. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother. Pharmacol., 33: 273-280, 1994.
7. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun., 219: 778-783, 1996.
8. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
9. 2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
10. 2-checkpoint inhibitor. Clin. Cancer Res., 2: 791-797, 1996.
11. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gate keeper and its intruders, camptothecins. Semin. Oncol., 23: 1-10, 1996.
12. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
13. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogs as anticancer agents. J. Natl. Cancer Inst., 85: 271-287, 1993.
14. Dancey, J., and Eisenhauer, E. A. Current perspectives on camptothecins in cancer treatment (Editorial). Br. J. Cancer, 74: 327-338, 1996.
15. Goldwasser, F., Bae, I. S., Torres, K., and Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon cell lines from the National Cancer Institute anticancer screen. Cancer Res., 55: 2116-2121, 1995.
16. 2-phase arrest and cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56: 4430-4437, 1996.
17. Rodrigues, N. R., Rowan, A., Smith, M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and Lane, D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA, 87: 7555-7559, 1990.
18. 2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J. Biol. Chem., 268: 8298-8308, 1992.
19. Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res., 55: 228-231, 1995.
20. 2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
21. 2 arrest in Chinese hamster ovary cells. Cancer Res., 50: 3761-3766, 1990.
22. Gibbs, E., Pan, Z. Q., Niu, H., and Hurwitz, J. Studies on the in vitro phosphorylation of HSSB-p34 and -p107 by cyclin-dependent kinases: cyclin-substrate interactions dictate the efficiency of phosphorylation. J. Biol. Chem., 271: 22847-22854, 1996.
23. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA. 90: 3988-3992, 1993.
24. Paulovich, A. G., and Hartwell, L. H. A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell, 82: 841-847, 1995.
25. Larner, J. M., Lee, H., and Hamlin, J. L. Radiation effects on DNA synthesis in a defined chromosomal replicon. Mol. Cell. Biol., 14, 1901-1908, 1994.
26. 1-to-S phase transition. Mol. Cell. Biol., 15: 2612-2624, 1995.
27. 1 in mammalian fibroblasts. Science (Washington DC), 259: 1908-1912, 1993.
28. 2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell, 66: 731-742, 1991.
29. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., and Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J., 11: 961-971, 1992.
30. Voitenleitner, C., Fanning, E., and Nasheuer, H-P. Phosphorylation of DNA polymerase α-primase by cyclin A-dependent kinases regulates initiation of DNA replication in vitro. Oncogene, 14: 1611-1615, 1997.
31. Nurse, P. Universal control mechanism regulating onset of M-phase. Nature (Lond.), 344: 503-508, 1990.
32. O'Connor, P. M., and Kohn, K. W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells. Semin. Cancer Biol., 3: 409-416, 1992.
33. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
34. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
35. Tsao, Y. P., Russo, A., Nyamusa, G., Silber, R., and Liu, L. F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res., 53: 5908-5914, 1993.
36. Jayaraman, J., and Prives, C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell, 81: 1021-1029, 1995.
37. Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene, 10: 1053-1059, 1995.
38. Fan, S., Smith, M. L., Rivet, D. J., II, Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
39. 1 checkpoint-competent cells. Cancer Res., 55: 1639-1642, 1995.
40. 2 delay. Cancer Res., 55: 1643-1648, 1995.